Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Brigham and Women's Hospital · Harvard University · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
873
total citations
- FWCI
- 65.68
- Percentile
- 100%
- References
- 25
Citations per year
Authors
62- PMPaul M. RidkerCorresponding
Brigham and Women's Hospital, Harvard University
- JMJean MacFadyen
Brigham and Women's Hospital, Harvard University
- BMBrendan M Everett
Brigham and Women's Hospital, Harvard University
- PLPeter Libby
Brigham and Women's Hospital, Harvard University
- TTTom Thurén
Novartis (Switzerland), Novartis (United States)
Topics & keywords
Topics
Keywords
- Canakinumab
- Medicine
- Internal medicine
- Hazard ratio
- Myocardial infarction
- Placebo
- Adverse effect
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.